



COPY

10519515 - GAL 1654
2 of 4
JN

Certificate of Mailing 37 C.F.R. §1.8(a)

Hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to **MAIL STOP AMENDMENT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Signing Certificate: _____

Renee Conti

October 28, 2005

Date

Renee Conti

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: Kyl L. Smith

§
§
§
§
§
§
§

Conf. No.: 2543

§ Group Art Unit: 1654

Appln. No.: 10/519,515

§ Examiner: Not Yet Assigned

Filing Date: December 7, 2004

§ Attorney Docket No.: 681132-2US

Title: COMPOSITIONS FOR IMPROVING METAL PERFORMANCE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

Enclosed is an Information Disclosure Citation Form PTO/SB/08A and/or 08B in accordance with 37 C.F.R. § 1.98(a)(1) and (a)(2) listing all patents, publications, applications, and/or other information being submitted for consideration which may be material to the patentability of this application and/or for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. Also enclosed are copies of each of the foreign patents and/or non-patent literature documents cited therein but not copies of any U.S. patents and/or U.S. patent application publications in accordance with 37 C.F.R. § 1.98(a)(2). However, we will provide copies upon request.


The filing of this Information Disclosure Statement shall not be construed as an admission that any of the listed documents constitutes prior art, nor as an admission against interest in any manner.

No fee is believed to be due in connection with the filing of this Information Disclosure Statement since it is being filed before the mailing date of the first Office Action on the merits. However, the Commissioner is hereby authorized to charge any deficiencies or credit any overpayments to Deposit Account No. 50-1017.

It is respectfully requested that this Information Disclosure Statement and the documents listed on the attached Form PTO/SB/08A and/or 08B be considered and acknowledged by the Examiner in connection with the above-identified patent application, be made of record therein, and that the listed document(s) be cited in the issued patent.

Respectfully submitted,

Kyl L. Smith




Aaron R. Ettelman
Attorney for Applicant
Registration No. 42,516
Direct Dial: 215-965-1240
E-Mail: aettelman@akingump.com

October 28, 2005
(Date)

Akin Gump Strauss Hauer & Feld LLP
One Commerce Square
2005 Market Street, Suite 2200
Philadelphia, PA 19103
Telephone No.: 215-965-1200
Fax No.: 215-965-1210

ARE:rc
Enclosures


Form PTO/SB/08			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
(use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	1	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	CENACCHI T, BERTOLDIN T, FARINA C, FIORI MG, CREPALDI G. "Cognitive decline in the elderly: A double blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration." <i>Aging Clin Exp Res</i> , 5:123-133 (1993).	
	CROOK TH, TINKLENBERG J, YESAVAGE J, PETRIE W, NUNZI MG, MASSARI DC. "Effects of phosphatidylserine in age-associated memory impairment." <i>Neurology</i> , 41:644-649 (1991).	
	AMADUCCI L, CROOK TH, LIPPI A, BRACCO L, BALDERESCHI M, LATORRACA S, PIERSANTI P, TESCO G, SORBI S. "Use of phosphatidylserine in Alzheimer's disease." <i>Annals NYAcadSci</i> , 640:245-249 (1991).	
	CROOK T, PETRIE W, WELLS C, MASSARI DC. "Effects of phosphatidylserine in Alzheimer's disease." <i>Psychopharmacol Bull</i> , 28:61-66 (1992).	
	TOFFANO G, BATTISTELLA A, ORLANDO P. "Pharmacokinetics of radiolabelled brain phosphatidylserine." <i>Clin Trials J</i> , 24:18-24 (1987).	
	NISHIZUKAY. "Turnover of inositol phospholipids and signal transduction." <i>Science</i> , 225:1365-1370 (1984).	
	COHEN SA, MULLER WE. "Age-related alterations of NMDA-receptor properties in the mouse forebrain: Partial restoration by chronic phosphatidylserine treatment." <i>Brain Res</i> , 584:174-180 (1992).	
	BALL MJ. "Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study." <i>Ada Neuropath</i> , 37:111-118 (1977).	
	SCHEIBEL ME, LINDSAY RD, TOMIYASU U, SCHEIBEL AB. "Progressive dendritic changes in the aging human limbic system." <i>Exptl Neurol</i> , 53:420-430 (1976).	
	LIPPAAS, CRITCHETTDJ, EHLERTF, YAMAMURAHI, ENNASJ, BARTUSRT. "Age-related alterations in neurotransmitter receptors: An electrophysiological and biochemical analysis." <i>Neurobiol Aging</i> , 2:3-8.(1981).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

Form PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number		10/529,515	
		Filing Date		December 7, 2004	
		First Named Inventor		Kyl L. Smith	
		Group Art Unit		1654	
		Examiner Name		Not Yet Assigned	
Sheet	2	of	29	Attorney Docket Number 681132-2US	

U.S. PATENT DOCUMENTS				
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY
	Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS						
Exr Initials	Foreign Patent Document			Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁
	Country Code	Number	Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.				T ₁
	PEPEU G, SPIGNOLI G. "Nootropic drugs and brain cholinergic mechanisms." <i>Prog Neuro-Psychopharmacol Biol Psychiat</i> , 13 :S77-S88 (1989).				
	BARTUS RT, DEAN RL, BEER B, LIPPA AS. "The cholinergic hypothesis of geriatric memory dysfunction." <i>Science</i> , 217:408-417 (1982).				
	PETERSEN RC, JACK CR, JR, XU YC, WARING SC, O'BRIEN PC, SMITH GE, IVNIK RJ, TANGLOS EG, BOEVE BF, KOKMEN E. "Memory and MRI-based hippocampal volumes in aging and AD." <i>Neuro</i> , 54:581-587 (2000).				
	CORWIN J, DEAN RL, BARTUS RT, ROTROSEN J, WATKINS DL. "Behavioral effects of phosphatidylserine in the aged Fischer 344 rat: Amelioration of passive avoidance deficits without changes in psychomotor task performance." <i>Neurobiol</i>				
	ZANOTTI A, APORTI F, TOFFANO G, VALZELLI L. Effects of phosphatidylserine on avoidance relearning in rats. <i>Pharmacol Res Commun</i> , 16:485-493 (1984).				
	DRAGO F, CANONICO PL, SCAPAGNINI U. "Behavioral effects of phosphatidylserine in aged rats." <i>Neurobiol Aging</i> 2:209-213 (1981).				
	APORTI F, BORSATO R, CALDERINI G, RUBINI R, TOFFANO G, ZANOTTI A, VALZELLI L, GOLDSTEIN L. "Age-dependent spontaneous EEG bursts in rats: Effects of brain phosphatidylserine." <i>Neurobiol Aging</i> , 7:115-120 (1986).				
	ZANOTTI A, VALZELLI L, TOFFANO G. "Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats." <i>Psychopharmacol</i> , 99:316-321 (1989).				
	CASAMENTI F, MANTOVANI P, AMADUCCI L, PEPEU G. "Effect of phosphatidylserine on acetylcholine output from the cerebral cortex of the rat." <i>J Neurochem</i> , 32:529-533 (1979).				
	NUNZI MG, MILAN F, GUIDOLIN D, TOFFANO G. DENDRITIC "Spine loss on hippocampus of aged rats. Effect of brain phosphatidylserine administration." <i>Neurobiol Aging</i> , 8:501-510 (1987).				

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	3	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Foreign Patent Document		Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY
	Country Code	Number Kind Code (if known)		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.	T ₁
	NUNZI MG, MILAN F, GUIDOLIN D, POLATO P, TOFFANO G. "Effects of phosphatidylserine administration on age-related structural changes in the rat hippocampus and septal complex." <i>Pharmacopsychiat</i> , 22:125-128 (1989).	
	HEISS W-D, SZELIES B, KESSLER J, HERHOLZ K. "Abnormalities of energy metabolism in Alzheimer's disease studied with PET." <i>Annals NY Acad Sci</i> , 640:65-71 (1991).	
	VILLARDITA C, GRIOLI S, SALMERI G, NICOLETTI F, PENNISI G. "Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration." <i>Clin Trials J</i> , 4:84-93 (1987).	
	PALMIERI G, PALMIERI R, INZOLI MR, LOMBARDI G, SOTTINI C, TAVOLATO B, GIOMETTO B. "Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration." <i>Clin Trials J</i> , 24:73-83 (1987).	
	AMADUCCI L. "Phosphatidylserine in the treatment of Alzheimer's disease: Results of a multicenter study." <i>Psychopharmacol Bull</i> , 24:130-134 (1988).	
	DELWAIDE PJ, GYSERYNCK-MAMBOURG AM, HURLET A, YLIEFF M. "Double-blind randomized controlled study of phosphatidylserine in senile demented patients." <i>Acta Neurol Scand</i> , 73:136-140 (1986).	
	ENGEL RR. "Double-blind cross-over study of phosphatidylserine vs. placebo in subjects with early cognitive deterioration of the Alzheimer type." <i>Eur Neuropsychopharmacol</i> , 2:149-155 (1992).	
	SCHREIBER S, KAMPF-SHERF O, GORFINE M, KELLY D, OPPENHEIM Y, LERER B. "An open trial of plant-source derived phosphatidylserine for treatment of age-related cognitive decline." <i>Isr J Psychiatry Relat Sci</i> , 37:302-307 (2000).	
	MAGGIONI M, PICOTTI GB, BONDILOTTI GP, PANERAI A, CENACCHI T, NOBILE P, BRAMBILLA F. "Effects of phosphatidylserine therapy in geriatric patients with depressive disorders." <i>Acta Psychiatr Scand</i> , 81:265-270 (1990).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Form PTO/SB/08A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 29

Complete if Known

Application Number	10/519,515
Filing Date	December 7, 2004
First Named Inventor	Kyl L. Smith
Group Art Unit	1654
Examiner Name	Not Yet Assigned
Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS

Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY
	Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS

Exr Initials	Foreign Patent Document		Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁
	Country Code	Number Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.	T ₁
	CENACCHI T, BAGGIO C, PALIN E. "Human tolerability of oral phosphatidylserine assessed through laboratory examinations." <i>Clin Trials J</i> , 24:125-131 (1987).	
	HEISS WD. "Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease." <i>Cognitive Deterioration</i> , 5:88-98 (1994).	
	SINFORIANI E, AGOSTINIS C, MERLO P, GUALTIERI S, MAURI M, MANCUSO A. "Cognitive decline in ageing brain. Therapeutic approach with phosphatidylserine." <i>Clin Trials Jim</i> , 24:115-125.	
	GRANATA Q, DIMICHELE J. "Phosphatidylserine in elderly patients. An open trial." <i>Clin Trials J</i> , 24:99-103 (1987).	
	ALLEGRO L, FAVARETTO V, ZILLOTTO G. "Oral phosphatidylserine in elderly patients with cognitive deterioration. An open study." <i>Clin Trials J</i> , 24:104-108 (1987).	
	CAFFARA P, SANTAMARIA V. "The effects of phosphatidylserine in patients with mild cognitive decline. An open trial." <i>Clin 7Wa/s./</i> , 24:109-114 (1987).	
	ROSADINI G, SANNITA WG, NOBILI F, CENACCHI T. "Phosphatidylserine: Quantitative EEG effects in healthy volunteers." <i>Neuropsychobiol</i> , 24:42-48 (1990-1991).	
	HEISS W-D, KESSLER J, SLANSKY I, MIELKE R, SZELIES B, HERHOLZ K. "Activation PET as an instrument to determine therapeutic efficacy in Alzheimer's disease." <i>Annals NYAcad Sci</i> , 695:327-331 (1993).	
	FILBURN CR. "Dietary supplementation with phospholipids and docosahexaenoic acid for age-related cognitive impairment." <i>J Am Nutraceutical Assoc</i> , 3:45-55 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	5	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		T ₁
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	
	PEVET P, BUIJS RM, MASSON-PEVET M. "Effect of pinealectomy and a constant high level of circulating melatonin or of 5-methoxytryptamine on the vasopressinergic innervation in the brain of the European hamster (<i>Cricetus cricetus</i> , L)." <i>J Neural Transm</i> , 70:287-294 (1987).	
	KLINKHAMMER P, SZELIES, HEISS W-D. "Effect of phosphatidylserine on cerebral glucose metabolism in Alzheimer's disease." <i>Dementia</i> , 1:197-201 (1990).	
	LATORRACA S, PIERSANTI P, RESCO G, PIACENTINI S, AMADUCCI L, SORBI S. "Effect of phosphatidylserine on free radical susceptibility in human diploid fibroblasts." <i>J Neural Transm</i> , 6:73-77 (1993).	
	COLODNY L, HOFFMAN RL. "Inositol - clinical applications for exogenous use." <i>Alternative MedRev</i> , 3:432-447 (1998).	
	BARKAI AI, DUNNER DL, GROSS HA, MAYO P, FIEVE RR. "Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder." <i>Biol Psychiatry</i> , 13:65-72 (1978).	
	LEVINE J, BARAK Y, GONZALVES M, SZOR H, ELIZUR A, KOFMAN O, BELMAKER RH. "Double-blind, controlled trial of inositol treatment of depression." <i>Am J Psychiatry</i> , 152:792-794 (1995).	
	LEVINE J, BARAK Y, KOFMAN O, BELMAKER RH. "Follow-up and relapse analysis of an inositol study of depression." <i>Isr J Psychiatry Relat Sci</i> , 32:14-21 (1995).	
	BENJAMIN J, LEVINE J, FUX M, AVIV A, LEVY D, BELMAKER RH. "Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder." <i>Am J Psychiatry</i> , 152:1084-1086 (1995).	

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	6	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS			
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)
			Name of Applicant of Cited Document
			Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	T ₁
Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.	
IKEMOTO A, KOBAYASHI T, EMOTO K, UMEDA M, WATANABE S, OKUYAMA H. "Effects of docosahexaenoic and arachidonic acids on the synthesis and distribution of aminophospholipids during neuronal differentiation of PC 12 cells." <i>Arch Biochem Biophys</i> , 364:67-74 (1999).	
GREEN P, GLOZMAN S, KAMENSKY B, YAVIN E. "Developmental changes in rat brain membrane lipids and fatty acids: The preferential prenatal accumulation of docosahexaenoic acid." <i>JLipidRes</i> , 40:960-966 (1999).	
STEVENS LJ, ZENTALL SS, DECK JL, ABATE ML, WATKINS BA, LIPP SR, BURGESS JR. "Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder." <i>Am J Clin Nutr</i> , 62:761-768 (1995).	
STEVENS LJ, ZENTALL SS, ABATE ML, KUCZEK T, BURGESS JR. "Omega-3 fatty acids in boys with behavior, learning, and health problems." <i>Physiol Behav</i> , 59:915-920 (1996).	
JONES CR, ARAI T, RAPOPORT SI. "Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse." <i>Neurochem Res</i> , 22:663-670 (1997).	
ITOKAZU N, Ikegaya Y, NISHIKAWA M, MATSUKI N. "Bidirectional actions of docosahexaenoic acid on hippocampal neurotransmissions in vivo." <i>Brain Res</i> , 862:211-216 (2000).	
NISHIKAWA M, KIMURA S, AKAIKE N. "Facilitatory effect of docosahexaenoic acid on JV-methyl-D-aspartate response in pyramidal neurons of rat cerebral cortex." <i>J Physiol</i> , 475:83-93 (1994).	
POLING JS, VICINI S, ROGAWSKI MA, SALEM N, JR. "Docosahexaenoic acid block of neuronal voltage-gated K ⁺ channels: Subunit selective antagonism by zinc." <i>Neuropharmacol</i> , 35:969-982 (1996).	

Examiner Signature	Date Considered
---------------------------	------------------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	7	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY
				T ₁

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.
	SIMOPOULOS A. "Omega-3 fatty acids in health and disease and in growth and development." <i>Am J Clin Nutr</i> 191, 54:438-463.
	DELION S, CHALON S, GUILLOTEAU D, LEJEUNE B, BESNARD J-C, DURAND G. "Age-related changes in phospholipids fatty acid composition and monoaminergic neurotransmission in the hippocampus of rats fed a balanced or an n-3 polyunsaturated fatty acid-deficient diet." <i>JLipidRes</i> , 38:680-689 (1997).
	YODIM KA, MARTIN A, JOSEPH JA. "Essential fatty acids and the brain: Possible health implications." <i>Int J Dev Neurosci</i> , 18:383-399 (2000).
	ADAMS PB, LAWSON S, SANIGORSKI A, SINCLAIR AJ. "Arachidonic to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression." <i>Lipids</i> , 31 :S 167-S176 (1996).
	KALMIJN S, FESKENS EJM LAUNER LJ, KROMHOUT D. "Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men." <i>Am J Epidemiol</i> , 145:33-41 (1997).
	NEWMAN PE. "Could diet be one of the causal factors of Alzheimer's disease?" <i>Med Hypotheses</i> , 39:123-126 (1992).
	OKADA M, AMAMOTO T, TOMONAGA M, KAWACHI A, YAZAWA K, MINE K, FUJIWARA M. "The chronic administration of docosahexaenoic acid reduces the spatial cognitive deficit following transient forebrain ischemia in rats." <i>Neurosci</i> , 71:17-25 (1996).
	SHIKANO M, MASIZAWA Y, YAZAWA K. "Effect of docosahexaenoic acid on the generation of platelet-activating factor by eosinophilic leukemia cells, EoL-1." <i>J Immunol</i> , 150:3525-3533 (1993).

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	8	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Foreign Patent Document Country Code	Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.		
	CORNFORD EM, BRAUN LD, OLDENDORF WH. "Carrier mediated blood-brain barrier transport of choline and certain choline analogs." <i>J Neurochem</i> , 30:299-308.		
	ZEISEL SH, DA COSTA K-A, FRANKJIN PD, ALEXANDER EA, LAMONT JT, SHEARD NF, BEISER A. CHOLINE, "An essential nutrient for humans." <i>FASEB J</i> , 5:2093-2098 (1991).		
	WURTMAN RJ, HIRSCH MJ, GROWDON JH. "Lecithin consumption raises serum-free- choline levels." <i>Lancet</i> , 2M-69 (1977)		
	BLUSZTAJN JK, WURTMAN RJ. "Choline and cholinergic neurons." <i>Science</i> , 221:614-620 (1983).		
	DAVIS KL, MOHS RC, TINKLENBERG JR, HOLLISTER LE, PFEFFERBAUM A, KOPELL BS. "Cholinomimetics and memory. The effect of choline chloride." <i>Arch Neurol</i> , 37:49-52 (1980).		
	MOHS RC, DAVIS KL, TINKLENBERG JR, HOLLISTER LE. "Choline chloride effects on memory in the elderly." <i>Neurobiol Aging</i> , 1:21-25 (1981).		
	BUCHMN AL, SOHEL M, BROWN M, JENDEN DJ, AHN C, ROCH M, BRAWLEY TL. "Verbal and visual memory improve after choline supplementation in long-term total parenteral nutrition: A pilot study." <i>JPETV</i> , 25:30-35 (2001).		
	SITARAM N, WEINGARTNER H, GILLIN JC. "Human serial learning: Enhancement with arecholine and choline and impairment with scopolamine." <i>Science</i> , 210:274-276 (1978).		
	SITARAM N, WEINGARTNER H, CAINE ED, GILLIN JC. "Choline: Selective enhancement of serial learning and encoding of low imagery words in man." <i>Life Sci</i> , 22:1555-1560 (1978).		
	SU T-Z, CAMPBELL GW, OXENDER DL. "Glutamine transport in cerebellar granule cells in culture." <i>Brain Res</i> , 757:69-78 (1997).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	9	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.		
	POW DV, ROBINSON SR. "Glutamate in some retinal neurons is derived solely from glia." <i>Neurosci</i> , 60:355-366 (1994).		
	KAPETANOVIC IM, YONEKAWA WD, KUPFERBERG HJ. "Time-related loss of glutamine from hippocampal slices and concomitant changes in neurotransmitter amino acids." <i>JNeurochem</i> , 61:865-872 (1993).		
	NIHARA Y, ZEREZ CR, AKIYAMA DS, TANAKA KR. "Oral L-glutamine therapy for sickle cell anemia: 1. Subjective clinical improvement and favorable change in red cell NAD redox potential." <i>Am JHematol</i> , 58:117-121 (1998).		
	GELLER SJ. "Comparison of a tranquilizer and a psychic energizer." <i>JAMA</i> , 174:481-484 (1960).		
	LEWIS JA, YOUNG R. "Deanol and methylphenidate in minimal brain dysfunction." <i>Clin Pharmacol Ther</i> , 17:534-540 (1975).		
	ZS-NAGY I, FLOYD RA. "Electron spin resonance spectroscopic demonstration of the hydroxyl free radical scavenger properties of dimethylaminoethanol in spin trapping experiments confirming the molecular basis for the biological effects of centrophenoxine." <i>Arch Gerontol Geriatr</i> , 3:297-310 (1984).		
	OETTINGER L. "The use of Deanol in the treatment of disorders of behavior in children." <i>JPediatr</i> : 671-675.		
	FERRIS SH, SATHANANTHAN G, GERSHON S, CLARK C. "Senile dementia: Treatment with Deanol." <i>J Am Geriatr Soc</i> , 25:241-244 (1977).		
	DIMPFFEL W, HOFNRAN HC, PROHASKA A, SCHOBER F, SCHELLENBERG R. "Source density analysis of functional topographical EEG: Monitoring of cognitive drug action." <i>Eur JMed Res</i> , 1:283-290 (1995-1996).		
	VED HS, KOENIG ML, DAVE JR, DOCTOR BP. "Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate." <i>NeuroReport</i> , 8:963-968 (1997).		

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	10	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document
	Number	Kind Code (if known)	Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Foreign Patent Document			Name of Applicant of Cited Document
	Country Code	Number	Kind Code (if known)	Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.		
	CHENG DH, REN H, TANG X-C. "Huperaine A, a novel promising acetylcholinesterase inhibitor." <i>NeuroReport</i> , 8:97-101 (1996).		
	HANIN I, TANG X-C, KINDEL GL, KOZIKOWSKI AP. "Natural and synthetic Huperzine A: Effect on cholinergic function <i>in vitro</i> and <i>in vivo</i> ." <i>Annals NY Acad Sci</i> 695:304-306 (1993).		
	TANG X-C. "Huperzine A (Shuangyiping): promising drug for Alzheimer's research." <i>Ada Pharmacol Sinica</i> , 17:481-484 (1996).		
	XIONG ZQ, HAN YF, TANG X-C. "Huperzine A ameliorates the spatial working memory impairments induced by AF64A." <i>NeuroReport</i> , 6:2221-2224 (1995).		
	PERRY EK, TOMLINSON BE, BLESSED G, BERGMANN K, GIBSON PH, PERRY RH. "Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia." <i>Br MedJ</i> , 2:1457-1459 (1978).		
	WILCOCK GK, ESIRI MM, BOWEN DM, SMITH CCT. "Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities." <i>JNeuroSci</i> , 57:407-417 (1982).		
	THAI LJ, MASUR DM, BLAU AD, FULD PA, KLAUBER MR. "Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease." <i>J Am GeriatrSoc</i> , 37:42-48 (1989).		
	SUMMERS WK, MAJOVSKI LV, MARSH GM, TACHIKI K, KLING A. "Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type." <i>NewEnglJMed</i> , 315:1241-1245 (1986).		
	XU S-S, CAI Z-Y, QU Z-W, YANG R-M, CAI Y-L, WANG G-Q, SU X-Q, ZHONG X-S, CHENG R-Y, XU W-A, LI J-X, FENG B. "Huperzine-A in capsules and tablets for treating patients with Alzheimer's disease." <i>Ada Pharmacol Sinica</i> , 20:486-490 (1999).		
	XU S-S, GAO Z-X, WENG Z, DU Z-M, XU W-A, YANG J-S, ZHANG M-L, TONG Z-H, FANG Y-S, CHAI X-S, LI S-L. "Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease." <i>Ada Pharmacol Sinica</i> , 16:391-395 (1995).		
Examiner Signature	Date Considered		



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	11	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.
	SUN Q-Q, XU S-S, PAN J-L, GUO H-M, CAO W-Q. "Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students." <i>Ada Pharmacol Sinica</i> , 20:601-603 (1999).
	DRAGO F, VALERLO C, D'AGATA V, ASTUTO C, SPADARO F, CONTINELLA G, SCAPAGNINI U. "Pyroglutamic acid improves learning and memory capacities in old rats." <i>Functional Neurol</i> , 3:137-143 (1988).
	DRAGO F, CONTINELLA G, VALERIO C, D'AGATA V, ASTUTO C, SPADARO F, SCAPAGNINI U. "Effects of pyroglutamic acid on learning and memory processes of the rat." <i>Acta Therapeutica</i> , 13:587-594 (1987).
	SPIGNOLI G, MAGNANI M, GIOVANNINI MG, PEPEU G. "Effect of pyroglutamic acid stereoisomers on ECS and scopolamine-induced memory disruption and brain acetylcholine levels in the rat." <i>Pharmacol Res Commun</i> , 19:901-912 (1987).
	GRIOLI S, LOMEO C, QUATTROPANI MC, SPIGNOLI G, VILLARDITA C. "Pyroglutamic acid improves the age associated memory impairment." <i>Fundam Clin Pharmacol</i> , 4:169-173 (1990).
	SINGH HK, DHAWAN BN. "Neuropsychopharmacological effects of the Ayurvedic nootropic <i>Bacopa monniera</i> Linn. (Brahmi)." <i>Indian J Pharmacol</i> , 29:S359:S365 (1997).
	MORGAN M, BONE K. "Brahmi (Bacopa) - revered Ayurvedic herb." <i>Modern Phytotherapist</i> , 5:21-27 (1999).
	SINGH HK, DHAWAN BN. "Effect of <i>Bacopa monniera</i> Linn. (Brahmi) extract on avoidance responses in rat." <i>J Ethnopharmacol</i> , 5:205-214 (1982).
	SINGH HK, RASTOGI RP, SRIMAL RC, DHAWAN BN. "Effect of bacosides A and B on avoidance responses in rats." <i>Phytother Res</i> , 2:70-75 (1988).
	BHATTACHARYA SK, GHOSAL S. "Anxiolytic activity of a standardized extract of <i>Bacopa monniera</i> : An experimental study." <i>Phytomed</i> , 5:77-82 (1998).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	12	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document
	Number	Kind Code (if known)	
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS						
Exr Initials	Foreign Patent Document			Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁
	Country Code	Number	Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.					T ₁
	DAR A, CHANNA S. "Calcium antagonistic activity of <i>Bacopa monniera</i> on vascular and intestinal smooth muscles of rabbit and guinea-pig." <i>J Ethnopharmacol</i> , 66:167-174 (1999).					
	SINGH RH, LALLAN S. "Studies on the anti-anxiety effect of the <i>Medhya Rasayana</i> drug, <i>Brahmi</i> (<i>Bacopa monniera</i> Wettst.) - Part I." <i>J Res Ayurveda Siddha</i> , 1-133-148 (1980).					
	GHOSH S, KAR SK. "Clinical trial on Brahmi - Part II. Psychological investigation with normals." <i>J Exptl Med Sci</i> , 10:12-13 (1996).					
	SHARMA R, CHATURVEDI C, TEWARI PV. "Efficacy of <i>Bacopa monnieri</i> in revitalizing intellectual functions in children." <i>J Res Indian Med</i> , 3:1-17 (1987).					
	SHARMA, R., C. CHATURVEDIE AND P.V. TEWARI. "Management of Tropical Pulmonary Eosinophilia in Children with Ayurvedic Drugs," <i>J Res Indian Med</i> 1987; 3:1 -2.					
	ABHANG R. "Study to evaluate the effect of a micro (<i>Suksma</i>) medicine derived from Brahmi (<i>Herpestis monierd</i>) on students of average intelligence." <i>J Res Ayurveda Siddha</i> , 14:10-24 (1993).					
	MARTIS G, RAO A, KARANTH KS. "Neuropharmacological activity of <i>Herpestis monniera</i> ." <i>Fitoterapia</i> , 63:3 99-404 (1992).					
	SARA SJ, DEVAUGES V. "Priming stimulation of locus coeruleus facilitates memory retrieval in the rat." <i>Brain Res</i> , 438:299-303 (1988).					
	DENOBLEVJ. "Vinpocetine enhances retrieval of a step-through passive avoidance response in rats." <i>Pharmacol Biochem Behavior</i> , 26:183-186 (1987).					
	GROO D, PALOSI E, SZPORNLY L. "Comparison of the effects of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats." <i>Drug Develop Res</i> , 15:75-85 (1988).					
	BENCSTH P, DEBRECZENI L, TAKACS L. "Effect of ethyl apovincamine on cerebral circulation of dogs under normal conditions and in arterial hypoxia." <i>Arzneim- Forsch (Drug Res)</i> , 26:1920-1923 (1976).					

Examiner Signature	Date Considered
---------------------------	------------------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	13	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.
	RISCHKE R, KRIEGLSTEIN J. "Protective effect of vinpocetine against brain damage caused by ischemia." <i>Japn J Pharmacol</i> , 56:349-356 (1991).
	SAUER D, RISCHKE R, BECK T, ROBBERG C, MENNEL H-D, BIELENBERG GW, KRIEGLSTEIN J. "Vinpocetine prevents ischemic cell damage in rat hippocampus." <i>Life Sci</i> , 43:1733-1739 (1988).
	LAKICS V, SEBESTYEN MG, ERDO SL. "Vinpocetine is a highly potent neuroprotectant against veritridine-induced cell death in primary cultures of rat cerebral cortex." <i>NeurosciLett</i> , 185:127-130 (1995).
	NICHOLSON CD. "Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia." <i>Psychopharmacol</i> , 101:147-159 (1990).
	TRETTET L, ADAM-VIZI V. "The neuroprotective drug vinpocetine prevents veratridine-induced [Na ⁺] _i and [Ca ²⁺] _i rise in synaptosomes." <i>NeuroReport</i> , 9:1849-1853 (1998).
	ERDO SL, CAI N-S, WOLFF JR., KISS B. "Vinpocetine protects against excitotoxic cell death in primary cultures of rat cerebral cortex." <i>Eur J Pharmacol</i> , 187:551-553 (1990).
	MIYAMOTO M, MURPHY TH, SCHNAAR RL, COYLE JT. "Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line." <i>J Pharmacol Exptl Ther</i> , 250:1132-1140 (1989).
	ISHIHARA K, KATSUKI H, SUGIMURA M, SATOH M. "Idebenone and vinpocetine augment long-term potentiation in hippocampal slices in the guinea pig." <i>Neuropharmacol</i> , 28:569-573 (1989).
	COLESTON DM, HINDMARCH I. "Possible memory-enhancing properties of vinpocetine." <i>Drug Develop Res</i> , 14:191-193 (1988).
	PAULO T, TOTTH PT, NGUYEN TT, FORGACS L, TOROK TL, MAGYAR K. "HJNoradrenaline-releasing action of vinpocetine in the isolated main pulmonary artery of the rabbit." <i>J Pharm Pharmacol</i> , 38:668-673 (1986).

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	14	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS			
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)
			Name of Applicant of Cited Document
			Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.		
	KARPATI E, SZPORNY L. "General and cerebral haemodynamic activity of ethyl apovincamate." <i>Arzneim-Forsch (Drug Res)</i> , 26:108-1912 (1976).		
	IMAMOTO T, TANABE M, SHIMAMOTO N, KAWAZOE K, HIRATA M. "Cerebral circulatory and cardiac effects of vinpocetine and its metabolite, apovincaminic acid, in anesthetized dogs." <i>Arzneim-Forsch (Drug Res)</i> , 34:161-169 (1984).		
	HAGIWARA M, ENDO T, HIDAKA H. "Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle." <i>Biochem Pharmacol</i> , 33:453-457(1984).		
	HADJIEV D, YANCHEVA S. "Rheoencephalographic and psychological studies with ethyl apovincamate in cerebral vascular insufficiency." <i>Arzneim-Forsch (Drug Res)</i> , 26:1947-1950 (1976).		
	SHIBOTA M, KAKIHANA M, NAGAOKA A. "The effect of vinpocetine on the brain glucose uptake in mice." <i>Folia Pharmacol Japon</i> , 80:221-224 (1982).		
	ROSDY B, BALAZS M, SZPORNY L. "Biochemical effect of ethyl apovincamate." <i>Arzneim-Forsch (Drug Res)</i> , 26:1923-1926 (1976).		
	PANTANO P, BARON J-C, LEBRUN-GRANDIE P, DUQUESNOY N, BOUSSER M-G, COMAR D. "Regional cerebral blood flow and oxygen consumption in human aging." <i>Stroke</i> 15:635-641 (1984).		
	MIYAZAKI M. "The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases." <i>Angiology</i> , 46:53-58 (1995).		
	OTOMO E, ATARASHI J, ARAKI G, ITO E, OMAE T, KUZUYA F, NUKADA T, EBI O. "Comparison of vinpocetine with ifenprodil tartrate and dihydroergotamine mesylate treatment and results of long-term treatment with vinpocetine." <i>Curr Ther Res</i> 19%5,37%ol 1-821.		
	MANCONI E, BINAGHI F, PITZUS F. "A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin." <i>Curr Ther Res</i> , 40:702-709 (1986).		

Examiner Signature	Date Considered
---------------------------	------------------------

OCT 31 2005



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	15	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document
	Number	Kind Code (if known)	
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Foreign Patent Document			Name of Applicant of Cited Document
	Country Code	Number	Kind Code (if known)	
				Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	BALESTRERI R, FONTANA L, ASTENGO F. "A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction." <i>J Am Geriatr Soc</i> , 35:425-430 (1987).	
	HINDMARCH I, FUCHS H-H, ERZIGKEIT H. "Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes." <i>Internal Clin Psychopharmacol</i> , 6:31-43 (1991).	
	SUBHAN Z, HINDMARCH I. "Psychopharmacological effects of vinpocetine in normal healthy volunteers." <i>Eur J Clin Pharmacol</i> , 28:567-571 (1985).	
	RICE-EVANS CA, MILLER NJ, PAGANGA G. "Structure-antioxidant activity relationships of flavonoids and phenolic acids." <i>Free Rad Biol Med</i> , 20:933- 956 (1996).	
	RIGO A, VIANELLO F, CLEMENTI G. "Contribution of proanthocyanidins to the peroxy radical scavenging capacity of some Italian red wines." <i>J Agric Food Chem</i> , 48:1996-2002 (2000).	
	BAGCHI D, GARG A, KROHN RL, BAGCHI DJ, BALMOORI J, STOHS SJ. "Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA- induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice." <i>Gen Pharmacol</i> , 30:771-776 (1998).	
	FREI B, KIM MC, AMES BN. "Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations." <i>Proc Natl Acad Sci</i> , 87:4879- 4883 (1990).	
	FACINO RM, CARINI M, ALDINI G, BOMBARDELLI E, MORAZZONI P, MORELLI R. "Free radicals scavenging action and anti-enzyme activities of procyanidines from <i>Vitis vinifera</i> ." <i>Arzneim-Forsch (Drug Res)</i> , 44:592-601 (1994).	
	BAGCHI B, GARG A, KROHN RL, BAGCHI M, TRAN MX, STOHS SJ. "Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract <i>in vitro</i> ." <i>Res Commun Molecular Pathol Pharmacol</i> , 95:179-189 (1997).	

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	16	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document
	Number	Kind Code (if known)	
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS					
Exr Initials	Foreign Patent Document		Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁
	Country Code	Number Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.	T ₁
	PACKER L, RIMBACH G, VIRGILI F. "Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (<i>Pinus maritima</i>) bark, pycnogenol." <i>Free Rad Biol Med</i> , 27:704-724 (1999).	
	LIU FJ, ZHANG YX, LAU BHS. "Pycnogenol enhances immune and haemopoietic functions in senescence-accelerated mice." <i>Cell Mol Life Sci</i> , 54:1168-1172 (1998).	
	SALAH N, MILLER NJ, PAGANGA G, TUBURG L, BOLWELL GP, RICE-EVANS C. "Polyphenolic flavonoids as scavengers of aqueous phase radicals and as chain-breaking antioxidants." <i>Arch Biochem Biophys</i> , 322:339-346 (1995).	
	COSSINS E, LEE R, PACKER L. "ESR studies of vitamin C regeneration, order of reactivity of natural source phytochemical preparations." <i>Biochem Mol Biol Intern</i> , 45:583-597 (1998).	
	SAJA A, SCALESE M, LANZA M, MARZULLO D, BONINA F, CASTELLI F. "Flavonoids as antioxidant agents: Importance of their interaction with biomembranes". <i>Free Rad Biol Med</i> , 19:481-486 (1995).	
	RONG Y, LI L, SHAH V, LAU BHS. "Pycnogenol protects vascular endothelial cells from r-butyl hydroperoxide induced oxidant injury." <i>Biotechnol Ther</i> , 5:117-126 (1994-1995).	
	WEI ZH, PENG QL, LAU BHS. "Pycnogenol enhances endothelial cell antioxidant defenses." <i>Redox Report</i> , 3:219-224 (1997).	
	KIM J, CHEHADE J, PINNAS JL, MOORADIAN AD. "Effect of select antioxidants on malondialdehyde modification of proteins." <i>Nutrition</i> , 16:1079-1081 (2000).	
	UEDA T, UEDA T, ARMSTRONG D. "Preventive effect of natural and synthetic antioxidants on lipid peroxidation in the mammalian eye." <i>Ophthalmic Res</i> , 28:184-192 (1996).	
	KOBAYASHI MS, HAN D, PACKER L. "Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity." <i>Free Rad Res</i> , 32:115-124 (2000).	
	COYLE JT, PUTTFARCKEN P. "Oxidative stress, glutamate, and neurodegenerative disorders." <i>Science</i> , 262:689-695 (1993).	

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	17	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document
	Number	Kind Code (if known)	
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS					
Exr Initials	Foreign Patent Document		Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁
	Country Code	Number Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.
	OLNEY JW. "Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate." <i>Science</i> , 164:719-721 (1969).
	PEREIRA CMF, OLIVEIRA CR. "Glutamate toxicity on a PC 12 cell line involves glutathione (GSH) depletion and oxidative stress." <i>Free Rad Biol Med</i> , 23:637-647 (1997).
	FITZPATRICK DF, BING B, ROHDEWALD P. "Endothelium-dependent vascular effects of pycnogenol." <i>J Cardiovasc Pharmacol</i> , 32:509-515 (1998).
	SCHMIDT HHHW, WALTER U. "No at work" <i>Cell</i> , 78:919-925 (1994).
	FREMONT L, BELGUENDOZ L, DELPAL S. "Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids." <i>Life Sci</i> , 64:2511-2521 (1999).
	CHEN CK, PACE-ASCIAC CR. "Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta." <i>Gen Pharmacol</i> , 27:363-366 (1996).
	ABALAN F. "Primer in folic acid: Folate and neuropsychiatry." <i>Nutrition</i> , 15:595-598 (1999).
	ALPERT JE, FAVA M. "Nutrition and depression: The role of folate." <i>Nutr Rev</i> , 55:145-149 (1997).
	ABOU-SALEH MT, COPPEN A. "The biology of folate in depression: Implications for nutritional hypotheses of the psychoses." <i>J Psychiat Res</i> , 20:91-101 (1986).
	BOTTIGLIERI T, LAUNDY M, CRELLIN R, TOONE BK, CARNEY MWP, REYNOLDS EH. "Homocysteine, folate, methylation, and monoamine metabolism in depression." <i>J Neurol Neurosurg Psychiatry</i> , 69:228-232 (2000).
	ENZI G. "Folate status and cognitive impairment." <i>Aging Clin Exp Res</i> , 6:69-72 (1994).
	ORTEGA RM, MANAS LR, ANDRES P, GASPARD MJ, AGUDO FR, JIMENEZ A, PASCUAL T. "Functional and psychic deterioration in elderly people may be aggravated by folate deficiency." <i>J Nutr</i> , 126:1992-1999 (1996).

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	18	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY
			/

FOREIGN PATENT DOCUMENTS				
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY
				T ₁

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.		
	FAVA M, BORUS JS, ALPERT JE, NIERENBERG AA, ROSENBAUM JF, BOTTIGLIERI T. "Folate, vitamin B12, and homocysteine in major depressive disorder." <i>Am J Psychiatry</i> , 154:426-428 (1997).		
	LEVITT AJ, JOFFE RT. "Folate, B12, and life course of depressive illness." <i>Biol Psychiatry</i> , 25:867-872 (1989).		
	GHADIRIAN AM, ANANTH J, ENGELSMANN F. "Folic acid deficiency and depression." <i>Psychosomatics</i> , 21:926-929 (1980).		
	PRAKASH R, PETRIE WM. "Psychiatric changes associated with an excess of folic acid." <i>Am J Psychiatry</i> , 139:1192-1193 (1982).		
	CLARKE R, SMITH AD, JOBST KA, REFSUM H, SUTTON L, UELAND PM. "Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease." <i>Arch Neurol</i> , 55:1449-1455 (1998).		
	RIGGS KM, SPIRO A, TUCKER K, RUSH D. "Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance on the Normative Aging Study." <i>Am J Clin Nutr</i> , 63:306-314 (1996).		
	SNOWDON DA, TULLY CL, SMITH CD, RILEY KP, MARKESBERY WR. "Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: Findings from the Nun study." <i>Am J Clin Nutr</i> , 1:993-998 (2000).		
	CARNEY M, SHEFFIELD BF. "Associations of subnormal serum folate and vitamin B12 and effects of replacement therapy." <i>J Nerv Ment Dis</i> , 150:404-412 (1970).		
	LEVITT AJ, WESSON VA, JOFFE RT. "Impact of suppression of thyroxine on folate status during acute antidepressant therapy." <i>Psychiatry Res</i> , 79:123-129 (1998).		
	CRAYHON R. "The clinical applications of folic acid." <i>J Amer Nutraceutical Assoc</i> , 4:21-26 (2001).		

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	19	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document
	Number	Kind Code (if known)	
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS					
Exr Initials	Foreign Patent Document		Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁
	Country Code	Number Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	UBBINK JB. "Should all elderly people receive folate supplements?" <i>Drugs Aging</i> , 13:415-420 (1998).	
	KAUWELL GP, LIPPERT BL, WILSKY CE, HERRLINGER-GARCIA K, HUTSON AD, THERIAQUE DW, RAMPERSAUD GC, CERDA JJ, BAILEY LB. "Folate status of elderly women following moderate folate depletion responds only to a higher folate intake." <i>J Afa/r</i> , 130:1584-1590 (2000).	
	LANDGREN F, ISRAELSSON B, LINDGREN A, HULTBERG B, ANDERSSON A, BRATTSTROM L. "Plasma homocysteine in acute myocardial infarction: Homocysteine-lowering effect of folic acid." <i>J Intern Med</i> , 237:381-388 (1995).	
	KELLY PJ, ROSAND J, PLOMARITOGLOU A, CHANG Y, KISTLER JP, FURIE KL. "Mild-to-moderate hyperhomocyst(e)inemia and risk of stroke. Result of a meta-analysis." <i>Stroke</i> , 32:366 (2000).	
	MALINOW MR, NIETO FJ, SZKLO M, CHAMBLESS LE, BOND G. "Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults." <i>The Atherosclerosis Risk in Communities Study</i> . <i>Circulation</i> , 87:1107-1113 (1993).	
	SELHUB J, JACQUES PJ, BOSTOM AG, D'AGOSTINO RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Rush D, Schaefer EJ, Rosenberg IH. "Relationship between plasma homocysteine, vitamin status and extracranial carotid artery stenosis in the Framingham study population." <i>J Nutr</i> , 126:1258S-1265S (1996).	

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	20	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY
	Country Code			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	PANCHARUNITI N, LEWIS CA, SAUBERLICH HE, PERKINS LL, GO RCP, ALVAREZ JO, MACALUSO M, ACTON RT, COPELAND RB, COUSINS AL, GORE TB, CORNWELL PE, ROSEMAN JM. "Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease." <i>Am J Clin Nutr</i> , 59:940- 948 (1994).	
	STAMPFER MJ, MALINOW R, WILLETT WC, NEWCOMER LM, UPSON B, ULLMANN D, TISHLER PV, HENNEKENS CH. "A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians." <i>JAMA</i> , 268:877-881 (1992).	
	SELHUB J, JACQUES PF, BOSTOM AG, D'AGOSTINO RB, WILSON PWF, BELANGER AJ, O'LEARY DH, WOLF PA, SCHAEFER EJ, ROSENBERG IH. "Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis." <i>New Engl J Med</i> , 332:286-291 (1995).	
	CLARKE R, DALY L, ROBINSON K, NAUGHTEN E, CAHALANE S, FOWLER B, GRAHAM I. "Hyperhomocysteinemia: An independent risk factor for vascular disease." <i>New Engl J Med</i> 1991;324:U9-U55.	
	BOUSHEY CJ, BERESFORD SAA, OMENN GS, MOTULSKY AG. "A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes." <i>JAMA</i> , 274:1049-1057 (1995).	
	KANG S-S, WONG PWK, MALINOW MR. "Hyperhomocyst(e)mia as a risk factor for occlusive vascular disease." <i>Annu Rev Nutr</i> , 12:279-298 (1992).	
	EVERS S, KOS HG, GROTENMEYER KH, <i>et al</i> . "Features, symptoms, and neurophysiological findings in stroke associate with hyperhomocysteinemia." <i>ArchNeurol</i> , 54:1276 (1997).	
	PERNA AF, DE SANTO NG, INGROSSO D. "Adverse effects of hyperhomocysteinemia and their management by folic acid." <i>Miner Electrolyte Metab</i> , 23:174-178 (1997).	

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	21	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.
	HARKER LA, ROSS R, SLICHTER SJ, SCOTT CR. "Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis." <i>J Clin Invest</i> , 58:731-741 (1976).
	BLANN AD. "Endothelial cell damage and homocysteine." <i>Atherosclerosis</i> , 94:89-91 (1994).
	LA RUE A, KOEHLER KM, WAYNE SJ, CHIULLI SJ, HAALAND KY, GARRY PJ. "Nutritional status and cognitive functioning in a normally aging sample: A 6-yr reassessment." <i>Am J Clin Nutr</i> , 65:20-29 (1997).
	LIPTON SA, KIM WK, CHOI YB, KUMAR S, D'EMILIA DM, RAYUDU PV, ARNELLE DR, STAMLER JS. "Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor." <i>Proc Natl Acad Sci</i> , 94:5923-5928 (1997).
	BEAL MF, SWARTZ KJ, FINN SF, MAZUREK MF, KOWALL NW. "Neurochemical characterization of excitotoxin lesions in the cerebral cortex." <i>J Neurosci</i> , 11:147-158 (1991).
	UBBINK JB, VAN DER MERWE A, VERMAAK WJH, DELPORT R. "Hyperhomocysteinemia and the response to vitamin supplementation." <i>Clin Invest</i> , 71:993-998 (1993).
	BROUWER I A, VAN DUSSELDORP M, THOMAS CMG, DURAN M, HAUTVAST JGAI, ESKES KB, STEEGERS-THEUNISSEN RPM. "Low-dose folic acid supplementation decreases plasma homocysteine concentrations: A randomized trial". <i>Am J Clin Nutr</i> , 69:99-104 (1999).
	BUNOUT D, GARRIDO A, SUAZO M, KAUFFINN R, VENEGAS P, DE LA MAZA P, PETERMANN M, HIRSCH S. "Effects of supplementation with folic acid and antioxidant vitamins on homocysteine levels and LDL oxidation in coronary patients." <i>Nutrition</i> , 16:107-110 (2000).

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	22	of	29	Application Number	10/519,515
				Filing Date	December 7, 2004
				First Named Inventor	Kyl L. Smith
				Group Art Unit	1654
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS

Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS

Exr Initials	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.	T ₁
	CLARKE R, ARMITAGE J. "Vitamin supplements and cardiovascular risk: Review of the randomized trials of homocysteine-lowering vitamin supplements." <i>Sem Thromb Hemostas</i> 2000, 26:341-348.	
	"Homocysteine Lowering Trialsists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomized trials." <i>Br MedJ</i> , 316:894-898 (1998).	
	WOO KS, CHOOK P, LOLIN YI, SANDERSON JE, METREWELI C, CELERMAJER DS. "Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia." <i>J Am Coll Cardiol</i> , 34:2002-2006 (1999).	
	CARNEY MWP, TOONE BK, REYNOLDS EH. "S-Adenosylmethionine and affective disorder." <i>Am J Med</i> , 83(suppl 5A): 104-106 (1987).	
	SHANE B. "Vitamin B12-Folate interrelationships." <i>Annu Rev Nutr</i> , 5:115-141 (1985).	
	SHEVELL MI, ROSENBLATT DS. "The neurology of cobalamin." <i>Can J Neurol Sci</i> , 19:472-486 (1992).	
	HECTOR M, BURTON JR. "What are the psychiatric manifestations of vitamin B12 deficiency?" <i>J Am Geriatr Soc</i> , 36:1105-1112 (1987).	
	MITSUYAMA Y, KOGOH H. "Serum and cerebrospinal fluid vitamin B12 levels in demented patients with CH3-B12 treatment - preliminary study." <i>Jpn J Psychiatr Neurol</i> , 42:65-71 (1988).	
	LINDENBAUM J, HEALTON EB, SAVAGE DG, BRUST JCM, GARRETT TJ, PODELL ER, MARCELL PD, STABLER SP, ALLEN RH. "Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis." <i>New Engl J Med</i> , 318:1720-1728 (1988).	
	BOHNEN N, JOLLES J, DEGENAAR CP. "Lower blood levels of vitamin B12 are related to decreased performance of healthy subjects in the Stroop color-word test." <i>Neurosci Res Commun</i> , 11:53-56 (1992).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Form PTO/SB/08A

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 23 of 29

Application Number 10/519,515
 Filing Date December 7, 2004
 First Named Inventor Kyl L. Smith
 Group Art Unit 1654
 Examiner Name Not Yet Assigned
 Attorney Docket Number 681132-2US

U.S. PATENT DOCUMENTS

Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY


FOREIGN PATENT DOCUMENTS

Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.	T ₁
	GOODWIN JS, GOODWIN JM, GARRY PJ. "Association between nutritional status and cognitive functioning in a healthy elderly population." <i>JAMA</i> , 249:2917-2921 (1983).	
	HEALTON EB, SAVAGE DG, BRUST JCM, GARRETT TJ, LINDENBAUM J. "Neurologic aspects of cobalamin deficiency." <i>Medicine</i> , 70:229-245 (1991).	
	CARMEL R. "Subtle and atypical cobalamin deficiency states." <i>Am J Hematol</i> , 34:108-114 (1990).	
	MITTENBERG W, SEIDENBERG M, O'LEARY DS, DIGIULIO DV. "Changes in cerebral functioning associated with normal aging." <i>J Clin Exptl Neuropsychol</i> , 11:918-932 (1989).	
	TETRUD JW, LANGSTON JW. "The effect of deprenyl (selegiline) on the natural history of Parkinson's disease." <i>Science</i> , 245:519-522 (1989).	
	AMERICAN MEDICAL ASSOCIATION. "Thiamin addition to alcohol." <i>Proceedings, 50th Interim Meeting, American Medical Association</i> .	
	TUCKER DM, PENLAND JG, SANDSTEAD HH, MILNE DB, HECK DG, KLEVAY LM. "Nutrition status and brain function in aging." <i>Am J Clin Nutr</i> , 52:93-102 (1990).	
	KLIMESCH W, SCHIMKE H, LADURNER G, PFURTSCHELLER G. "Alpha frequency and memory performance." <i>J Psychophysiol</i> , 4:381-390 (1990).	
	LONSDALE D, SHAMBERGER RJ. "Red cell transketolase as an indicator of nutritional deficiency." <i>Am J Clin Nutr</i> , 33:205-211 (1980).	
	BENTON D, FORDY J, HALLER J. "The impact of long-term vitamin supplementation on cognitive functioning." <i>Psychopharmacol</i> , 117:298-305 (1995).	
	BENTON D, GRIFFITHS R, HALLER J. "Thiamine supplementation mood and cognitive functioning." <i>Psychopharmacol</i> , 129:66-71 (1997).	
	ROOT EJ, LONGNECKER JB. "Brain cell alterations suggesting premature aging induced by dietary deficiency of vitamin B6 and/or copper." <i>Am J Clin Nutr</i> , 37:540-552 (1983).	

Examiner Signature	Date Considered
--------------------	-----------------

Form PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/519,515
				Filing Date	December 7, 2004
				First Named Inventor	Kyl L. Smith
				Group Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	24	of	29	Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS				
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS						
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.				T ₁
	MERRILL AH, JR, HENDERSON JM. "Diseases associated with defects in vitamin B6 metabolism or utilization." <i>Annu Rev Nutr</i> , 7:137-156 (1987).				
	DAKSHINAMURTI K, LEBLANCQ WD, HERCHL R, HAVLICEK V. "Nonparallel changes in brain monoamines of pyridoxine-deficient growing rats." <i>Exp Brain Res</i> , 26:355-366 (1976).				
	SIOW YL, DAKSHINAMURTI K. Effect of pyridoxine deficiency on aromatic L- amino acid decarboxylase in adult rat brain. <i>Exp Brain Res</i> , 59:575-581 (1985).				
	STEWART JW, HARRISON W, QUITKIN F, BAKER H. "Low B6 levels in depressed outpatients." <i>Biol Psychiatry</i> , 19:613-616 (1984).				
	CARNEY MWP. "Vitamin deficiency and mental symptoms." <i>BrJPsychiat</i> , 156:878-882 (1990).				
	KRETSCH MJ, SAUBERLICH HE, NEWBRUN E. "Electroencephalographic changes and periodontal status during short-term vitamin B-6 depletion of young, nonpregnant women." <i>Am J Clin Nutr</i> , 53:1266-1274 (1991).				
	ADAMS PW, WYNN V, ROSE DP, SEED M, FOLKARD J, STRONG R. "Effect of pyridoxine hydrochloride (vitamin B6) upon depression associated with oral contraception." <i>Lancet</i> , 1:897-904 (1973).				
	HALLERT C, ASTROM J, WALAN A. "Reversal of psychopathology in adult celiac disease with the aid of pyridoxine (vitamin B6)." <i>Scand J Gastroenterol</i> , 18:299-304 (1983).				
	DEIJEN JB, VAN DER BEEK EJ, ORLEBEKE JF, VAN DEN BERG H. "Vitamin B-6 supplementation in elderly men: Effects on mood, memory, performance and mental effort." <i>Psychopharmacol</i> 1992;109AS9-496.				
	BUETTNERGR. "The pecking order of free radicals and antioxidants: Lipid peroxidation, -tocopherol and ascorbate." <i>Arch Biochem Biophys</i> , 300:535- 543 (1993).				
	SCHMIDT R, HAYN M, REINHART B, ROOB G, SCHMIDT H, SCHUMACHER M, WATZINGER N, LAUNER LJ. "Plasma antioxidants and cognitive performance in middle-aged and older adults: Results of the Austrian Stroke Prevention Study." <i>J Am Geriatr Soc</i> , 46:1407-1410 (1998).				
Examiner Signature				Date Considered	



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/519,515
(use as many sheets as necessary)		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	25	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.		T ₁
	BEARD JL, CONNOR JD, JONES BC. "Brain iron: Location and function." <i>Prog Food SciNutrSci</i> 1993, 17:m-221.		
	Kretsch MJ, Fong AKH, Green MW, Johnson HL. Cognitive function, iron status, and hemoglobin concentration in obese dieting women. <i>Eur J Clin Nutr</i> 1998;52:512-518.		
	DALLMAN PR. "Biochemical basis for the manifestations of iron deficiency." <i>Annu Rev Nutr</i> , 6:13-40 (1986).		
	POLLITT E. "Iron deficiency and cognitive function," <i>Annu Rev Nutr</i> , 13:521-537 (1993).		
	DALLMAN PR, SIMES MA, STEKEL A. "Iron deficiency in infancy and childhood." <i>AmJ Clin Nutr</i> , 33:86-118 (1980).		
	POLLITT E, LEIBEL RL. "Iron deficiency and behavior." <i>JPediatr</i> , 88:372-381 (1976).		
	BRUNER AB, JOFFE A, DUGGAN AK, CASELLA JF, BRANDT J. "Randomized study of cognitive effects of iron supplementation in non-anemia iron-deficient adolescent girls." <i>Lancet</i> , 348:992-996 (1996).		
	BALLIN A, BERAR M, RUBINSTEIN U, KLETER Y, HERSHKOVITZ A. "Iron state in female adolescents." <i>AJDC</i> , 146:803-805 (1992).		
	GRONER JA, HOLTZMAN NA, CHARNEY E, MELLITS ED. "A randomized trial of oral iron on tests of short-term memory and attention span in young pregnant women." <i>J Adolescent Health Care</i> , 7:44-48 (1986).		
	PRASAD AS. "Zinc: An overview." <i>Nutrition</i> , 11:93-99 (1995).		
	TOREN P, ELDAR S, SELA B-A, WOLMER L, WEITZ R, INBAR D, KOREN S, REISS A, WEIZMAN R, LAOR N. "Zinc deficiency in attention-deficit hyperactivity disorder." <i>Biol Psychiatry</i> , 40:1308-1310 (1996).		
	CONSTANTINIDIS J. "The hypothesis of zinc deficiency in the pathogenesis of neurofibrillary tangles." <i>Med Hypotheses</i> , 3 5:319-323 (1991).		

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--



Form PB/ST/08A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 26 of 29

Complete if Known

Application Number	10/519,515
Filing Date	December 7, 2004
First Named Inventor	Kyl L. Smith
Group Art Unit	1654
Examiner Name	Not Yet Assigned
Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS

Exr Initials	U.S. Patent Document		Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY
	Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS

Exr Initials	Foreign Patent Document		Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁
	Country Code	Number Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.	T ₁
	BEKAROGLU M, ASLAN Y, GEDIK Y, DEGER O, MOCAN H, ERDURAN E, KARAHAN C. "Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: A research note." <i>J Child Psychol Psychiatr</i> , 37:225-227 (1996).	
	PENLAND JG. "Quantitative analysis of EEG effects following experimental marginal magnesium and boron deprivation." <i>Mag Res</i> , 8:341-358 (1995).	
	MOUNTOKALAKIS TD. "Effects of aging, chronic disease, and multiple supplements on magnesium requirements." <i>Magnesium</i> , 6:5-11 (1987).	
	FROZEL D, COPPEN A, MARKS V. "Plasma magnesium and calcium in depression." <i>Br J Psychiatr</i> , 115:1375-1377 (1969).	
	NIELSEN FH. "The justification for providing dietary guidance for the nutritional intake of boron." <i>Biol Trace Element Res</i> , 66:319-330 (1998).	
	HUNT CD, STOECKER BJ. "Deliberations and evaluations of the approaches, endpoints and paradigms for boron, chromium and fluoride dietary recommendations." <i>J Nutr</i> , 126:2441S-2451S (1996).	
	PENLAND JG. "Dietary boron, brain function, and cognitive performance." <i>Environ Health Perspect</i> , 102(suppl 7):65-72 (1994).	
	TOLMAN EL, BARRIS E, BURNS M, PANSINI A, PARTRIDGE R. "Effects of vanadium on glucose metabolism <i>in vitro</i> ." <i>Life Sci</i> , 25:1159-1164 (1979).	
	SHECHTER Y, KARLISH SJD. "Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions." <i>Nature</i> , 284:556-558 (1980).	
	CLAUSEN T, ANDERSEN TL, STUMP-JOHANSEN M, PETKOVA O. "The relationship between the transport of glucose and cations across cell membranes in isolated tissues. XI. The effect of vanadate on 45Ca-efflux and sugar transport in adipose tissue and skeletal muscle." <i>Biochimica Biophysica Acta</i> , 646:261-267 (1981).	
	CLARK AS, FAGAN JM, MITCH WE. "Selectivity of the insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle." <i>Biochem J</i> , 232:273-276 (1985).	

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	27	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Country Code	Foreign Patent Document Number	Kind Code (if known)	Name of Applicant of Cited Document
				Date of Publication of Cited Document MM-YYYY

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or country where published.		T ₁
	SEKAR N, KANTHASAMY A, WILLIAM S, SUBRAMANIAN S, GOVINDASAMY S. "Insulinic actions of vanadate in diabetic rats." <i>Pharmacol Res</i> , 22:207-217 (1990).		
	SAKURAI H, TSUCHIYA K, NUKATSUKA M, SOFIE M, KAWADA J. "Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats." <i>J Endocrinol</i> , 126:451-459 (1990).		
	PANDEY SK, ANAND-SRIVASTAVA MB, SRIVASTAVA AK. "Vanadyl sulfate-stimulated glucogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is independent of insulin receptor tyrosine phosphorylation." <i>Biochemistry</i> , 37:7006-7014 (1998).		
	COHEN N, HALBERSTAM M, SHLIMOVICH P, CHANG CJ, SHAMOON H, ROSETTI M. "Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus." <i>J Clin Invest</i> , 95:2501-2509 (1995).		
	CASTRO J, MAQUEDANO A, OLIVE M. "Lipid synthesis in isolated rat hepatocytes: Activation by insulin and vanadate and inhibition by ouabain." <i>Biochem Intern</i> , 9:413-420 (1984).		
	RODRIGUEZ-GIL JE, GOMEZ-FOIX AM, FILLAT C, BOSCH F, GUINOVART JJ. "Activation by vanadate of glycolysis in hepatocytes from diabetic rats." <i>Diabetes</i> , 40:1355-1359 (1991).		
	STANLEY BG, KYRKOULI SE, LAMPERT S, LEIBOWITZ SF. "Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity." <i>Peptides</i> , 7:1189-1192 (1986).		
	MORLEY JE, LEVINE AS, GOSNELL BA, KNEIP J, GRACE M. "Effect of neuropeptide Y on ingestive behaviors in the rat." <i>Am J Physiol</i> , 252:R599-R609 (1987).		
	BILLINGTON CJ, BRIGGS JE, GRACE M, LEVINE AS. "Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism." <i>Am J Physiol</i> , 260:R321- R327 (1991).		

Examiner Signature	Date Considered
---------------------------	------------------------




Form PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/519,515
		Filing Date	December 7, 2004
		First Named Inventor	Kyl L. Smith
		Group Art Unit	1654
		Examiner Name	Not Yet Assigned
Sheet	28	of	29
		Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS			
Exr Initials	U.S. Patent Document Number		Name of First Inventor of Cited Document
	Kind Code (if known)		
			Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS				
Exr Initials	Foreign Patent Document Number		Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY
	Country Code	Kind Code (if known)		
				T ₁

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	MALABU UH, DRYDEN S, MCCARTHY HD, KILPATRICK A, WILLIAMS G. "Effects of chronic vanadate administration in the STZ-induced diabetic rat. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding." <i>Diabetes</i> , 43:9-15 (1994).	
	BENTON D, COOK R. "Selenium supplementation improves mood in a double-blind crossover trial." <i>Psychopharmacol</i> , 102:549-550 (1990).	
	BENDICH A. "The potential for dietary supplements to reduce premenstrual syndrome (PMS) symptoms." <i>J Am Coll Nutr</i> , 19:3-12 (2000).	
	THYS-JACOBS S. "Micronutrients and the premenstrual syndrome: The case for calcium." <i>J Am Coll Nutr</i> , 19:220-227 (2000).	
	THYS-JACOBS S, CECCARELLI S, BIERMANA, WEISMAN H, COHEN M-A, ALVIR J. "Calcium supplementation in premenstrual syndrome: A randomized crossover trial." <i>J Gen Intern Med</i> , 4:183-189 (1989).	
	THYS-JACOBS S, STARKEY P, BERNSTEIN D, TIAN J. "Calcium carbonate and the premenstrual syndrome: Effects on premenstrual and menstrual symptoms." <i>Am J Obstet Gynecol</i> , 179:444-452 (1998).	
	PENLAND JG, JOHNSON PE. "Dietary calcium and manganese effects on menstrual cycle symptoms." <i>Am J Obstet Gynecol</i> , 168:1417-1423 (1993).	
	FACCHINETTI F, BORELLA P, SANCES G, FIORONI L, NAPPI R, GENAZZANI AR. "Oral magnesium successfully relieves premenstrual mood changes." <i>Obstet Gynecol</i> , 78:177-181 (1991).	
	FACCHINETTI F, SANCES G, BORELLA P, GENAZZANI AR, NAPPI G. "Magnesium prophylaxis pf menstrual migraine: Effects on intracellular magnesium." <i>Headache</i> , 31:298-301 (1991).	

Examiner Signature	Date Considered
--------------------	-----------------



Form PTO/SB/08A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 29 of 29

Complete if Known

Application Number	10/519,515
Filing Date	December 7, 2004
First Named Inventor	Kyl L. Smith
Group Art Unit	1654
Examiner Name	Not Yet Assigned
Attorney Docket Number	681132-2US

U.S. PATENT DOCUMENTS

Exr Initials	U.S. Patent Document Number	Kind Code (if known)	Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY

FOREIGN PATENT DOCUMENTS

Exr Initials	Foreign Patent Document Country Code	Number	Kind Code (if known)	Name of Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	T ₁

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T ₁
	DE SOUZA MC, WALKER AF, ROBINSON PA, BOLLAND K. "A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: A randomized, double-blind, crossover study." <i>J Women's Health & Gender-Based Med</i> , 9:131-139 (2000).	
	BENTON D, ROBERTS G. "Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren." <i>Lawcef</i> , 1:140-143 (1988).	
	SCHOENTHALER SJ, BIER ID. "Vitamin-mineral intake and intelligence: A macrolevel analysis of randomized controlled trials." <i>J Alternative Complementary Med</i> , 5:125-134 (1999).	

Examiner Signature	/Michele Flood/	Date Considered	06/21/2009
-----------------------	-----------------	--------------------	------------